Publications by authors named "Ingelise Gordon"

Claim this Profile
R
Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.
Kizzmekia Corbett-Helaire, Christian Dzuvor, Sydney Moak, Lindsay McManus, Abigail Thomas, Ingelise Gordon

Res Sq· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses.
Alexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, Matthew J Vukovich, Tek Malla, Ingelise J Gordon

Nat Microbiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.
Christian K O Dzuvor, Sydney Moak, Lindsay R McManus, Abigail Thomas, Abigail E Dzordzorme, Ingelise J Gordon

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.
Richard L Wu, Katherine V Houser, Martin R Gaudinski, Alicia T Widge, Seemal F Awan, Ingelise J Gordon

Lancet HIV· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Joseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, LaSonji A Holman, Cynthia S Hendel, Ingelise J Gordon

NPJ Vaccines· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
Seemal F Awan, Amarendra Pegu, Larisa Strom, Cristina A Carter, Cynthia S Hendel, Ingelise J Gordon

JCI Insight· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
Myra Happe, Amelia R Hofstetter, Jing Wang, Galina V Yamshchikov, LaSonji A Holman, Ingelise J Gordon

NPJ Vaccines· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Ingelise J Gordon

Lancet Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Ingelise J Gordon

Lancet Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.
Sarah F Andrews, Lauren Y Cominsky, Geoffrey D Shimberg, Rebecca A Gillespie, Jason Gorman, Ingelise Gordon

Sci Transl Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Alicia T Widge, Amelia R Hofstetter, Katherine V Houser, Seemal F Awan, Grace L Chen, Ingelise J Gordon

Sci Transl Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Christine Lee, Ingelise J Gordon

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia.
Roma V Rajput, Xiaoyang Ma, Kristin L Boswell, Martin Gaudinski, Ingelise Gordon

Br J Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.
Noemia S Lima, Maryam Musayev, Timothy S Johnston, Danielle A Wagner, Amy R Henry, Ingelise Gordon

Nat Commun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis is not significantly associated with COVID-19 disease severity.
Yifan Zhou, Ruba Shalhoub, Stephanie N Rogers, Shiqin Yu, Muxin Gu, Ingelise J Gordon

Blood· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Emily E Coates, Srilatha Edupuganti, Grace L Chen, Myra Happe, Larisa Strom, Ingelise Gordon

Lancet Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
Richard L Wu, Azza H Idris, Nina M Berkowitz, Myra Happe, Martin R Gaudinski, Ingelise J Gordon

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.
Noemia S Lima, Maryam Musayev, Timothy S Johnston, Danielle A Wagner, Amy R Henry, Ingelise Gordon

bioRxiv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.
Katherine V Houser, Martin R Gaudinski, Myra Happe, Sandeep Narpala, Raffaello Verardi, Ingelise J Gordon

EClinicalMedicine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Joseph P Casazza, Evan M Cale, Sandeep Narpala, Galina V Yamshchikov, Emily E Coates, Ingelise Gordon

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
Rolando Pajon, Nicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, Sijy O'Dell, Ingelise Gordon

N Engl J Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
Katherine V Houser, Grace L Chen, Cristina Carter, Michelle C Crank, Thuy A Nguyen, Ingelise J Gordon

Nat Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.
Nicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, Sijy O'Dell, Charlene McDanal, Ingelise Gordon

medRxiv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Amarendra Pegu, Sarah E O'Connell, Stephen D Schmidt, Sijy O'Dell, Chloe A Talana, Ingelise Gordon

Science· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Monoclonal Antibody for Malaria Prevention.
Martin R Gaudinski, Nina M Berkowitz, Azza H Idris, Emily E Coates, LaSonji A Holman, Ingelise J Gordon

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis